MaxCyte Inc reports results for the quarter ended December 31 - Earnings Summary

• MaxCyte Inc MXCT reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -5 cents. The mean expectation of five analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -15 cents to -11 cents per share.

• Revenue fell 44.5% to $8.69 million from a year ago; analysts expected $7.93 million.

• MaxCyte Inc's reported EPS for the quarter was a loss of 10 cents​.

• The company reported a quarterly loss of $10.6 million.

• MaxCyte Inc shares had fallen by 17.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the advanced medical equipment & technology peer group is also "strong buy"

Wall Street's median 12-month price target for MaxCyte Inc is $8.00

This summary was machine generated from LSEG data March 12 at 01:04 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)